- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06216899
Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial (mRE-EEN)
This study will compare the tolerability and efficacy of conventional formula Exclusive Enteral Nutrition (EEN) and whole-food blended smoothie EEN by enrolling a total of 60 participants with newly diagnosed pediatric Crohn's disease (CD).
Participants will be provided either commercial formula or guided on the preparation of the home-blended smoothie. These participants will be given a specific recipe, blender, and be provided the food components to the smoothie. The study will total 8 weeks and will assess tolerance, clinical outcomes, stool microbiome, and quality of life.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mason E Nuding
- Phone Number: 206-987-0055
- Email: mason.nuding@seattlechildrens.org
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3J 0C3
- Not yet recruiting
- Izaak Walton Killam Health Centre
-
Contact:
- Bradley MacIntyre MacIntyre
- Phone Number: 902-470-7009
- Email: Brad.MacIntyre@iwk.nshealth.ca
-
Principal Investigator:
- Anthony Otley, MD, MSc
-
-
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19146
- Not yet recruiting
- Children's Hospital of Philadelphia
-
Principal Investigator:
- Lindsey Albenberg, DO
-
Contact:
- Clarice Cook
- Phone Number: 445-942-7445
- Email: cookc4@chop.edu
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Sub-Investigator:
- David Suskind, MD
-
Contact:
- Danny Gagucas
- Phone Number: 206-987-1062
- Email: Danny.Gagucas@seattlechildrens.org
-
Principal Investigator:
- Dale Lee, MD, MSCE
-
Sub-Investigator:
- Betty Zheng, MD
-
Sub-Investigator:
- Ghassan Wahbeh, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 8 -21 years old.
- Diagnosis of Crohn's disease within 24 months
- Elevation in objective inflammatory markers at enrollment: C-reactive protein (CRP), ESR, or fecal calprotectin
- Active Crohn's disease, as defined by Pediatric Crohn's Disease Activity Index (PCDAI) ≥10.
- Participant capable of giving informed consent, or if a minor the parent/guardian is capable of giving informed consent.
Exclusion Criteria:
- History of surgery for Crohn's disease.
- Perianal disease as part of Crohn's disease phenotype.
- Recent use of:
- corticosteroids (within 4 weeks),
- dose adjustment of immunomodulator (within 8 week)
- azathioprine 4 weeks prior to study final visit (week 8)
- start or adjust methotrexate 3 weeks prior to final study visit.
- Prior use of biological medication
- Prior treatment with EEN or other dietary therapy for Crohn's disease.
- Prior treatment with antibiotics for Crohn's disease.
- Known allergies to any of the food components in the smoothie.
- Admission to hospital due to severity of Crohn's disease and associated symptoms.
- Unwillingness to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Smoothie
In the smoothie arm, you will be provided instructions, a blender, and food components to prepare the smoothie at home.
|
The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4.
At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
|
Active Comparator: Formula
In the formula arm, you will be given conventional formula as per the direction of the gastroenterology team along with our dieticians.
|
Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4.
At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerance- Ability to remain on prescribed nutritional therapy
Time Frame: 4 and 8 weeks
|
Tolerance of therapy as measured by ability to continue prescribed nutritional therapy over 4-weeks and 8-weeks without deviation from protocol.
Participants will meet with a study dietitian at week 2, week4, and week 8. Dietitians will evaluate caloric needs, specific deficits, and dietary limitations.
|
4 and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fecal Calprotectin reduction from baseline
Time Frame: 4 and 8 weeks
|
Fecal calprotectin (FCP) level <250 μg/gram
|
4 and 8 weeks
|
Pediatric Crohn's Disease Activity Index (PCDAI) reduction from baseline
Time Frame: 4 and 8 weeks
|
Pediatric Crohn's Disease Activity Index (PCDAI) score <10 (clinical remission). PCDAI will be calculated at each visit. The total score is calculated from assessments in 11 sections. Minimum score 0. Maximum score 100. A lower score is better. History (recall 1 week)
Physical Examination
Laboratory
|
4 and 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dale Lee, MD, MSCE, Seattle Children's Hospital, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00004459
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Whole-food based smoothie
-
University of RochesterTerminatedProteinuria | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 4United States
-
University of California, San DiegoRecruitingChronic Lymphocytic Leukemia Stage A(0)United States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteCompletedDiet Modification | CardiologyUnited States
-
Stanford UniversityCompletedDiet, HealthyUnited States
-
Mayo ClinicNot yet recruitingObstructive Sleep Apnea | Daytime SleepinessUnited States
-
Drexel UniversityCompletedObesity | OverweightUnited States
-
University of RochesterActive, not recruitingHypertension | Hyperlipidemias | Heart Disease, IschemicUnited States
-
The University of Texas Health Science Center at...Louise L Morrison TrustCompletedChronic Disease | Nutrition, HealthyUnited States
-
University of RochesterCompletedObesity | Diabetes Mellitus, Type 2 | Insulin Resistance | Nutritional and Metabolic DiseaseUnited States